Dr. Hagerman is medical director of the UC Davis MIND Institute and director of the Fragile X Research and Treatment Center. She has more than 20 years of experience in the field of neurodevelopmental disorders and is an internationally respected leader in fragile X research including fragile X syndrome, a genetic condition that is the leading cause of inherited intellectual disability and the leading single-gene cause of autism.
Dr. Hagerman, her husband, Dr. Paul Hagerman, and their research team are the discoverers of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS), a late-onset neurodegenerative disorder. Randi Hagerman conducts clinical research on individuals with fragile X-associated disorders, including children and adults with fragile X syndrome, adult males with FXTAS, and women with fragile-X related conditions, such as fragile X-associated primary ovarian insufficiency (FXPOI).
Dr. Randi Hagerman also conducts research that bridges the association between autism and fragile X syndrome. Her main area of research is on targeted treatments for neurodevelopmental disorders, including fragile X syndrome, autism, premutation disorders and Angelman syndrome.
Dr. Randi Hagerman has written more than 200 peer-reviewed articles and numerous book chapters on neurodevelopmental disorders, and has written several books on fragile X. They include a 3rd Edition of Fragile X Syndrome: Diagnosis, Treatment, and Research which was published in 2002 by Johns Hopkins University Press, and Neurodevelopmental Disorders: Diagnosis and Treatment, published by Oxford University Press in 1999. She serves on the editorial boards of the publications Journal of Developmental and Behavioral Pediatrics and Molecular Autism, and has worked to establish fragile X clinical programs and research programs throughout the world.
The National Fragile X Association in 2004 honored Randi and Paul Hagerman for their work on FXTAS, by establishing the Hagerman Award. It honored Randi Hagerman in 2008 with a Lifetime Achievement Award.
Professor and Endowed Chair in Fragile X Research
2825 50th St.
Sacramento, CA 95817
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
B.S., UC Davis, Davis, California, 1971
University of California, San Diego, La Jolla, California, 1979-80
American Society of Human Genetics
International Association for the Scientific Study of Intellectual Disabilities
National Fragile X Foundation
Scientific Council of L'Association Mosaiques (Paris)
Society for the Scientific Study of Behavioral Phenotypes
Society of Developmental and Behavioral Pediatrics
Western Society of Pediatric Research
Honors and Awards:
UC Davis Endowed Chair in Fragile X Research, 2005 to present,
Distinguished Professor, UC Davis, 2013,
Distinguished Alumni Award, UC Davis College of Biological Sciences, 2011,
Princeton Lecture Series Fellowship, 2010,
Lifetime Achievement Award, National Fragile X Foundation, 2008,
UC Davis Distinguished Scholarly Public Service Award, 2005,
UC Davis Dean’s Excellence in Mentoring Award, 2005,
Namesake (with Paul Hagerman), Hagerman Award for Research in FXTAS, International Association for the Study of Intellectual Deficiency, 2004,
IASSID Distinguished Achievement Award for Scientific Literature, 2004,
Bonfils-Stanton Foundation Award for Science including Medicine, 1993,
Jerrett Cole Award, National Fragile X Foundation, 1992,
Select Recent Publications:
Yang J-C, Simon C, Niu Y-Q, Bogost M, Schneider A, Tassone F, Seritan A, Grigsby J, Hagerman PJ, Hagerman RJ, Olichney JM. (2013) Phenotypes of hypofrontality in older female fragile X premutation carriers. ANN NEUROL 74:275-283.
Basuta K, Lozano R, Schneider A, Yrigollen C, Hessl D, Hagerman R, Tassone F. (2013) A family with two female siblings with compound heterozygous FMR1 premutation alleles. Clin Genet Jun 20 doi: 10.1111/cge.12218. [Epub ahead of print].
Wang JY, Hessl D, Schneider A, Tassone F, Hagerman RJ, Rivera SM. (2013) Fragile X-associated tremor/ataxia syndrome (FXTAS): influence of the FMR1 gene on motor fiber tracts in males with normal and premutation alleles. JAMA Neurol Aug 1; 70(8):1022-9.
Hagerman R, Hagerman P. (2013) Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome (FXTAS). Lancet Neurol 12(8):786-98.
Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F. (2013) High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 161A(8):1897-903.
Schneider A, Ligsay A, Hagerman RJ. (2013) Fragile X syndrome: An aging perspective. Dev Disabil Res Rev 18(1):68-74.
Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman R, Hessl D. (2013) Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharm 27(10):956-963. doi: 10.1177/0269881113494105.
Au J, Akins R, Berkoqitz-Sutherland L, Tang HT, Chen Y, Boyd A, Tassone F, Nguyen D, Hagerman R. (2013) Prevalence and risk of migraine headaches in adult fragile X premutation carriers. Clin Genet. Feb 1. doi: 10.1111/cge.12109 [Epub ahead of print].
Wang JY, Hagerman RJ, Rivera SM. (2013) A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Mov Disord. May 6 doi: 10.1002/mds.25473. [Epub ahead of print].
Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ. (2013) A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr. 34(3):147-155.
Kover ST, McDuffie AS, Hagerman RJ, Abbeduto L. (2013) Receptive Vocabulary in Boys with Autism Spectrum Disorder: Cross-sectional Developmental Trajectories. J Autism Dev Disord. Apr 16. [Epub ahead of print].
Hagerman R, Lauterborn J, Au J, Berry-Kravis E. (2012) Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 54:297-335.